Connect with us

Featured

Liberty (SCAN.V) (LDDFF) Announces Private Placement of Units

Joe Samuel

Published

on

penny stocks news

VANCOUVER and ATLANTA , Nov. 7, 2019 /CNW/ – Liberty Defense Holdings Ltd. (“Liberty”) (TSXV: SCAN, FRANKFURT : LD2, OTCQB: LDDFF), a leading concealed weapons detection company, is pleased to announce that it has arranged a non-brokered private placement of up to 10,870,000 units (“Units”) at a price of C$0.23 (the “Unit Price”) for aggregate gross proceeds of up to approximately C$2,500,000 (the “Offering”). Liberty will retain the option to increase the Offering to 15,217,000 Units for gross proceeds of up to approximately C$3,500,000 .

Each Unit will consist of one common share and one common share purchase warrant (a “Warrant”), with each whole Warrant entitling the holder to purchase one additional common share of the Company at a price of C$0.30 for 18 months following the closing of the Offering. The Warrants will be subject to an acceleration clause in the event the closing price of Liberty’s common shares is greater than C$0.45 for 10 consecutive trading days (the “Acceleration Event”). Liberty will give notice to the holders of the Acceleration Event and the Warrants will expire 30 days thereafter.

In connection with the Offering, Liberty has engaged Laurentian Bank Securities Inc. to act as its exclusive financial advisor for the Offering. The Company may pay finder’s fees in accordance with the policies of the TSX Venture Exchange in conjunction with the closing of the Offering.

The Company intends to use the net proceeds of the Offering to provide working capital and continue the advancement of HEXWAVE, specifically the targeted completion of the Alpha testing and the production of the initial Beta Units in Q1 2020.

All securities issued pursuant to the Offering will be subject to a statutory hold period expiring four months and one day from closing of the Offering. Completion of the Offering is subject to approval of the TSX Venture Exchange.

On Behalf of Liberty Defense
Bill Riker
CEO & Director

About Liberty Defense
Liberty provides security solutions for concealed weapon detection in high volume foot traffic areas and has secured an exclusive license from Massachusetts Institute of Technology ( MIT ), as well as a technology transfer agreement, for patents related to active 3D radar imaging technology that are packaged into the HEXWAVE product. The system is designed to provide discrete, modular and scalable protection to provide layered, stand-off detection capability. This is intended to provide a means to proactively counter evolving urban threats. The sensors with active 3D radar imaging and Artificial Intelligence (AI)-enhanced automatic detection are designed to detect metallic and non-metallic firearms, knives, explosives and other threats. Liberty is committed to protecting communities and preserving peace of mind through superior security detection solutions. Learn more: LibertyDefense.com

FORWARD-LOOKING STATEMENTS

When used in this press release, the words “estimate”, “project”, “belief”, “anticipate”, “intend”, “expect”, “plan”, “predict”, “may” or “should” and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. Although Liberty believes, in light of the experience of their respective officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in the forward-looking statements and information in this press release are reasonable, undue reliance should not be placed on them because the parties can give no assurance that such statements will prove to be correct. The forward-looking statements and information in this press release include, amongst others, information relating to completion of the Offering, the use of proceeds of the Offering, the completion of the Alpha testing of HEXWAVE and production of the initial Beta Units in Q1 2020, and the functionality of HEXWAVE. Such statements and information reflect the current view of Liberty. There are risks and uncertainties that may cause actual results to differ materially from those contemplated in those forward-looking statements and information.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. There are a number of important factors that could cause Liberty’s actual results to differ materially from those indicated or implied by forward-looking statements and information. Such factors include, among others: the failure of Liberty to find suitable purchasers for the Offering; the failure of Liberty to obtain approval of the TSX Venture Exchange of the Offering, management’s discretion as to the use of proceeds of the Offering; currency fluctuations; disruptions or changes in the credit or security markets; results of operation activities and development of projects; project cost overruns or unanticipated costs and expenses; and general developmenty, market and industry conditions. The parties undertake no obligation to comment on analyses, expectations or statements made by third parties in respect of their securities or their respective financial or operating results (as applicable).

Liberty cautions that the foregoing list of material factors is not exhaustive. When relying on Liberty’s forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Liberty has assumed that the material factors referred to in the previous paragraph will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. The forward-looking information contained in this press release represents the expectations of Liberty as of the date of this press release and, accordingly, are subject to change after such date. Liberty does not undertake to update this information at any particular time except as required in accordance with applicable laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE Liberty Defense Holdings Ltd.

View original content to download multimedia:  http://www.newswire.ca/en/releases/archive/November2019/07/c6481.html

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Liberty Defense Holdings Inc. Midam was hired for a period from 06/1/2019 – 9/30/2019 to publicly disseminate information about Liberty Defense Holdings Inc. including on the Website and other media including Facebook and Twitter. We were paid $250,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid $75,000 (CASH) by Liberty Defense Holdings AND HAVE EXTENDED coverage for a period from 11/1/2019 – 11/30/2019. We may buy or sell additional shares of Liberty Defense Holdings Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click For Full Disclaimer.

Continue Reading
Click to comment

Featured

Stock Price Newsletter – November 15, 2019

Joe Samuel

Published

on

best biotech stocks to trade now

3 Biotech Stocks To Watch As The Sector Heats Up

When it comes to building a portfolio, money managers almost always ask their clients to diversify their portfolio. That’s in order to hedge against market risks. Hence, an investor needs to explore a wide range of sectors and choose stocks from those. One of the hottest sectors lately is the biotech sector.

Continue Reading


Comcast (CMCSA) Enters The Streaming Business: How Far Can It Go?

There had been a lot of anticipation with regard to the ‘streaming wars’ for most of the year. At least it’s here, with the launch of Apple TV+ (AAPL) and Disney Plus (DIS). However, those two launches simply signify the commencement of the streaming wars.

See For Yourself


3 Pharma Stocks to Watch As The Sector Gets Attention In November

It is often noticed that investment experts ask people to diversify their money across sectors. More often than not, it is recommended that some attention should be allocated towards biotech stocks. The simple reason behind this is the fact that biotech stocks have proven to be fruitful companies and the sector continues to churn out winners.

Click To Read More

Continue Reading

Biotechnology

3 Biotech Stocks To Watch As The Sector Heats Up

A. Lawrence

Published

on

top biotech stocks to watch list

When it comes to building a portfolio, money managers almost always ask their clients to diversify their portfolio. That’s in order to hedge against market risks. Hence, an investor needs to explore a wide range of sectors and choose stocks from those. One of the hottest sectors lately is the biotech sector.

It has managed to generate impressive growth over the past decade and remains a potentially high growth space for investors. On that note, here is a quick look at two biotech stocks that should be tracked by investors.

Biotech Stocks To Watch #1: GT Biopharma (GTBP)

GT Biopharma (GTBP) is a clinical-stage, immuno-oncology biotech company focused on innovative treatments based on its patent-pending TriKE™ technology. GT Biopharma (GTBP) is in good company within this space. Obviously you have the biotech giants:Gilead Sciences, Inc. (NASDAQ:GILD), Incyte Corporation (NASDAQ:INCY), &Merck & Co. (NYSE:MRK). But according to a recent article that was published on The Motley Fool it may be time for investors to give their attention to the “little guys” aka the Small Cap Stocks.

Within this article, The Motley Fool talks about 3 “Out of favor” “Cancer Treatment Stocks.” One of the companies is a small-cap stock that, according to the article, “sports marquee oncology partnerships with Gilead Sciences, Incyte, as well as Merck.” 

top biotechnology stocks to watch today

Similarly, when investors look at GT Biopharma (GTBP) they will notice that the company is indeed a small-cap stock and like the company The Motley Fool mentioned, has ties to a large entity to help further its own corporate missions. GT Biopharma (GTBP) has deep ties to the University of Minnesota & its prestigious Masonic Cancer Center, a comprehensive cancer center designated by the National Cancer Institute. Thanks to this relationship, GT Biopharma has been able to capitalize on several key developments:

GT Biopharma (GTBP) announces that Tim Schacker, M.D., Jeffrey S. Miller, M.D., and their colleagues at the University of Minnesota presented data showing its HIV-TriKE™ was able to kill HIV infected cells in the reservoir

GT Biopharma (GTBP) Announces Solid Tumor Targeting TriKe™ Kills Non-small Cell Lung Cancer (NSCLC) Tumor Cells

Read more on GT Biopharma Here.

Biotech Stocks To Watch #2: Jaguar Health (JAGX)

The first biotech stock to consider is that of Jaguar Health Inc (NASDAQ:JAGX), which made a major announcement at the end of October. That has resulted in the major rally in the stock through November and so far, the stock has gained as much as 45%. The company had announced that its fully owned subsidiary Napo Pharmaceutical has agreed on a distribution agreement with TannerGAP.

TannerGAP is part of the larger Tanner Pharma Group and will distribute the product Mytesi in places at which it is not yet registered. At this point in time, Mytesi is registered in Israel, the United States and Canada. Recently Jaguar also appointed Ian Wendt as its Vice President of Commercial Strategy.

On November 14 the company announced that Georgetown University ‘s Data Safety Monitoring Committee (“DSMC”) has reviewed the interim analysis for futility for the third-party, investigator-initiated Phase 2 HALT-D study evaluating the effectiveness of Mytesi® (crofelemer) for symptomatic relief in HER2 positive breast cancer patients receiving chemotherapy with trastuzumab, pertuzumab, and docetaxel or paclitaxel or trastuzumab, pertuzumab, carboplatin, and docetaxel (the “Study”). The DSMC has notified the Principal Investigator that the Study is allowed to enroll to completion. Enrollment in the Study now exceeds 85%, and the treatment period for each patient is 3 months.

SPECIAL REPORT | What Curing Cancer & HIV Could Mean for This Company, Its Investors & The World!

Biotech Stocks To Watch #3: Therapix Biosciences (TRPX)

The other biotech stock that warrants attention is that of Therapix Biosciences Ltd (NASDAQ:TRPX). The company is involved in developing treatments that are CBD based and today it announced top line results from the Phase 2A clinical study of its product THX-110. The study revealed that the product did, in fact, have a positive effect on patients who are afflicted with obstructive sleep apnea (OSA).

The study was conducted at the Assuta Hashalom Medical Center located in Israel and it represents a major positive for Therapix. After the news broke, the rocketed by as much as 19.45% and has emerged as one of the biotech stocks to watch for the rest of the week.

SPECIAL REPORT | What Curing Cancer & HIV Could Mean for This Company, Its Investors & The World!

best penny stocks Clovis Oncology (CLVS)

Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), Midam has been paid $100,000 for a period from October 1, 2019 to November 15, 2019. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP). Click Here For Full Disclaimer.

Continue Reading

Entertainment

Comcast (CMCSA) Enters The Streaming Business: How Far Can It Go?

Joe Samuel

Published

on

stock market today

There had been a lot of anticipation with regard to the ‘streaming wars’ for most of the year. At least it’s here, with the launch of Apple TV+ (AAPL) and Disney Plus (DIS). However, those two launches simply signify the commencement of the streaming wars.

Comcast To Launch Own Streaming Service in 2020

comcast peacock

NBC Universal, owned by Comcast Corporation (NASDAQ:CMCSA), is all set to launch its own streaming service named Peacock in April next year and it is interesting to figure where it is going to stand with regards to the streaming wars. As everyone knows, content and pricing are the most important factors in this regard. Here is a closer look at Peacock.

According to reports, Peacock is apparently going to launch with as much as 15,000 hours worth of content for its users and it is also going to include such cult classic shows like ‘The Office’. More often than not, streaming services need a few ‘anchor shows’ in order to attract users and that seems to be in place at Peacock.

[MARKET PREVIEW] The $40 Billion Dollar Content Gold Rush

Content Providers Eager To Capitalize

Fearless Films Inc. (FERL) is a full-service production company with award-winning upper management. The company specializes in producing both short and feature films as well as scriptwriting and distribution.

Fearless Films has been developing its operations recently which has caught the interest of new investors. One development was a recent news press relating to an agreement with Victor Altomare, the Founder and President of Fearless. The company entered a Letter of Intent to acquire the rights of up to 12 movies from a library held by Mr. Altomare. The price of the acquisition is to be determined at a later date.

streaming cord cutting entertainment stocks

On October 31, Fearless Films (FERLannounced that further to its initial press release on the 16th, the Company has selected The Lunatic as the first film to be selected for appraisal and final negotiation. Fearless will engage an international accounting and advisory firm with a strong film industry practice to provide an independent valuation of the film, following which the company will enter into final negotiations on the purchase.

Companies like Fearless are looking to fill the content needs of companies streaming companies. Jeffrey Cole explained how Apple, for example, needs new content, “I think entertainment’s going to become a key element of Apple’s business. For them, spending $2 billion on [original content] is just dabbling. If they like what they see, I think they’ll have a $10 billion budget.” This is a massive market potential that Fearless Films is looking to capitalize on.

[MARKET PREVIEW] The $40 Billion Dollar Content Gold Rush

What’s In Store For Peacock?

However, it is highly interesting to note that Peacock is going to make an ad-supported free version of the platform available. Initially, it was supposed to be an option for Comcast cable or broadband customers only.

This pricing structure could throw the other companies into chaos, considering no one in the industry offers a free version at this point. Peacock expects to generate $5 per month per user from the free version. Apple TV+ is priced at $4.99 per month but it is free 12 months for users who have purchased a new Apple device. Disney Plus, on the other hand, is priced at $6.99 a month.

A yearly subscription will cost $69.99 a month. Another heavyweight that is going to join the arena in a few months is HBO Max and that is going to set back a customer $14.99 on a monthly basis. However, HBO Max will be available for free for AT&T customers. So, it is clear that the streaming space is heating up and Peacock has come up with a very interesting plan to make a mark.

movie stocks

Pursuant to an agreement between Midam Ventures LLC and Fearless Films Inc. (FERL), Midam has been paid $94,980 by Fearless Films Inc. (FERL) for a period from October 1, 2019 to November 17, 2019. We may buy or sell additional shares of Fearless Films Inc. (FERL) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Fearless Films Inc. (FERL). Click Here For Full Disclaimer.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com